CSIMarket
 


Astria Therapeutics inc   (ATXS)
Other Ticker:  
 
 

ATXS's Income from Cont. Operations Growth by Quarter and Year

Astria Therapeutics Inc 's Income from Cont. Operations results by quarter and year




ATXS Income from Cont. Operations (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December -31.41 -13.26 -9.49 -8.98
III Quarter September -17.73 -12.00 -7.87 -10.86
II Quarter June -12.57 -11.25 -31.90 -9.51
I Quarter March -11.19 -15.32 -170.08 -7.95
FY   -72.90 -51.83 -219.34 -37.30



ATXS Income from Cont. Operations fourth quarter 2023 Y/Y Growth Comment
Astria Therapeutics inc in the fourth quarter 2023 recorded loss from continued operations of $ -31.41 millions.

According to the results reported in the fourth quarter 2023, Astria Therapeutics Inc achieved the best Income from Cont. Operations growth in Major Pharmaceutical Preparations industry. While Astria Therapeutics Inc ' s Income from Cont. Operations no change of % ranks overall at the positon no. in the fourth quarter 2023.




ATXS Income from Cont. Operations ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Astria Therapeutics Inc 's fourth quarter 2023 Income from Cont. Operations $ -31.41 millions ATXS's Income Statement
Astria Therapeutics Inc 's fourth quarter 2022 Income from Cont. Operations $ -13.26 millions Quarterly ATXS's Income Statement
New: More ATXS's historic Income from Cont. Operations Growth >>


ATXS Income from Cont. Operations (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Astria Therapeutics Inc 's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ATXS's IV. Quarter Q/Q Income from Cont. Operations Comment
Recent accomplishment of -31.41 millions by Astria Therapeutics inc appear even less good compare to the loss from continued operations -17.73 millions in the third quarter.

Within Major Pharmaceutical Preparations industry Astria Therapeutics inc achieved highest sequential Income from Cont. Operations growth. While Astria Therapeutics Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


ATXS's IV. Quarter Q/Q Income from Cont. Operations Comment
IV. Quarter 2023 accomplishment of -31.41 millions by Astria Therapeutics inc come out even more unfavourable considering the -17.73 millions loss from continued operations a quarter before.

Within Major Pharmaceutical Preparations industry Astria Therapeutics inc achieved highest sequential Income from Cont. Operations growth. While Astria Therapeutics Inc 's Income from Cont. Operations growth quarter on quarter, overall rank is .


Astria Therapeutics Inc 's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Income from Cont. Operations 12 Months Ending $ -72.89 $ -54.75 $ -49.02 $ -47.70 $ -51.83
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Astria Therapeutics Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -73 millions in the Dec 31 2023 period.
The situation is detiriorating as the cumulative loss from continued operations is getting bigger from $ -54.75 millions for the period from Sep 30 2023 to Dec 31 2022 and $ -48.061 millions for the twelve months ending in the quarter a year ago.

Astria Therapeutics inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
Astria Therapeutics Inc ' has realized cumulative trailing twelve months loss from continued operations of $ -73 millions in the Dec 31 2023 period.
The results are worsening as the cumulative loss from continued operations is inflating from $ -54.75 millions in TTM ending quarter Sep 30 2023 and $ -48.061 millions for the twelve months ending in the quarter a year ago Eloise  K. Smith told.

Astria Therapeutics inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
ATXS's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for ATXS's Competitors
Income from Cont. Operations Growth for Astria Therapeutics Inc 's Suppliers
Income from Cont. Operations Growth for ATXS's Customers

You may also want to know
ATXS's Annual Growth Rates ATXS's Profitability Ratios ATXS's Asset Turnover Ratio ATXS's Dividend Growth
ATXS's Roe ATXS's Valuation Ratios ATXS's Financial Strength Ratios ATXS's Dividend Payout Ratio
ATXS's Roa ATXS's Inventory Turnover Ratio ATXS's Growth Rates ATXS's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Dec 31 2023
Align Technology inc 196.86%$ 196.862 millions
Alcon inc 190.75%$ 190.746 millions
Dexcom Inc 179.19%$ 179.194 millions
Icon Plc144.76%$ 144.764 millions
Vericel Corporation119.40%$ 119.402 millions
Novartis Ag113.57%$ 113.573 millions
Iqvia Holdings Inc 106.61%$ 106.608 millions
Davita Inc 103.75%$ 103.752 millions
Stryker Corp103.02%$ 103.020 millions
Enzon Pharmaceuticals inc 101.80%$ 101.802 millions
Surgery Partners Inc 100.43%$ 100.429 millions
Corcept Therapeutics Inc88.36%$ 88.364 millions
Intuitive Surgical Inc 81.38%$ 81.378 millions
Astrazeneca Plc81.02%$ 81.020 millions
Tactile Systems Technology Inc 77.49%$ 77.494 millions
Quest Diagnostics Inc76.72%$ 76.724 millions
Dr Reddy s Laboratories Limited76.21%$ 76.206 millions
3m Company74.40%$ 74.401 millions
Electromed Inc 71.34%$ 71.341 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com